Literature DB >> 3309195

CAF in metastatic breast cancer: standard therapy or another effective regimen?

D F Hayes, I C Henderson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3309195     DOI: 10.1200/JCO.1987.5.10.1497

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  6 in total

Review 1.  A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy.

Authors:  R Abraham; R L Basser; M D Green
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

2.  Doxorubicin for inflammatory breast cancer: a red humor for a red tumor?

Authors:  C M Legler; D F Hayes
Journal:  Ann Surg Oncol       Date:  1995-07       Impact factor: 5.344

Review 3.  Response to treatment of breast cancer.

Authors:  J L Berenberg
Journal:  Breast Cancer Res Treat       Date:  1991-05       Impact factor: 4.872

4.  Combination versus sequential single agent chemotherapy in advanced breast cancer: associations with metastatic sites and long-term survival. The Western Cancer Study Group and The Southeastern Cancer Study Group.

Authors:  R T Chlebowski; R V Smalley; J M Weiner; L E Irwin; A A Bartolucci; J R Bateman
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

5.  A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer.

Authors:  D I Jodrell; I E Smith; J L Mansi; M C Pearson; G Walsh; S Ashley; H D Sinnett; J A McKinna
Journal:  Br J Cancer       Date:  1991-05       Impact factor: 7.640

6.  Effective treatment of advanced breast cancer with vinorelbine, 5-fluorouracil and l-leucovorin plus human granulocyte colony-stimulating factor.

Authors:  G V Kornek; K Haider; W Kwasny; F Lang; G Krauss; M Hejna; M Raderer; G Weinländer; D Depisch; W Scheithauer
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.